

 aura\$80 Million
Follow-On Offering svb Securities
Lead-Left Bookrunner
November 2022

SVB Securities Serves as Lead-Left Bookrunner for Aura Biosciences' (Nasdaq: AURA) \$80 Million Follow-On Offering

Key Transaction Highlights

- Confidentially launched on November 28th, publicly launched November 30th (post-close), and priced overnight
- Well oversubscribed from both new and existing investors
- Consisted of 6,700,000 shares of common stock at a price of \$12.00 per share, representing a 13.0% discount to confidential launch
- Aura Biosciences intends to use the net proceeds from this offering together with existing cash, cash equivalents and marketable securities, to advance the clinical development of belzutopap serotatocan for the treatment of choroidal melanoma and NMIBC, to develop the platform and for general corporate purposes.
- This is SVB Securities' 2nd bookrun offering for Aura Biosciences and 47th bookrun equity offering in 2022.

If you would like to create the Best Bid indication, visit [svb.com](#). If you would like to create the Best bid at SVB Securities indication, visit [svb.com](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED OR OTHERWISE PASSED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES.

BOSTON
55 State Street
9th Floor
Boston, MA 02109

CHARLOTTE
217 York Trade Street
Suite 2100
Charlotte, NC 28202

NASHVILLE
400 Union Hill Boulevard
Suite 200
Nashville, TN 37219

NEW YORK
100 Avenue of the Americas
10th Floor
New York, NY 10009

SAN FRANCISCO
201 California Street
10th Floor
San Francisco, CA 94111